Source: PR Newswire

Press Release: NantHealth : CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc.

LOS ANGELES, Oct. 12, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has informed the Company that it...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Patrick Soon-Shiong's photo - Chairman & CEO of NantHealth

Chairman & CEO

Patrick Soon-Shiong

CEO Approval Rating


NantHealth is a cloud-based medical Information Technology platform that enables medical professionals to share and deliver healthcare information. Read more